Galmed Pharmaceutica (GLMD)

$0.60 +0.02 (2.83%)
Market Cap 3.29M
Revenue (ttm) 0.00
Net Income (ttm) -7.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 6,800
Avg Vol 53,602
Day's Range N/A - N/A
Shares Out 5.48M
Stochastic %K 20%
Beta 0.40
Analysts Hold
Price Target $12.00

Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 693 8448
Fax: 972 3 693 8447
Address:
16 Abba Hillel Road, Ramat Gan, Israel
madan_shatri
madan_shatri Mar. 21 at 10:15 AM
$GLMD What was the purpose of CEOs letter to SHs ? Short term valuation in terms of stock performance or asset/IP valuation ? Where is either of that ? From the day of that IMO SP lost 30% to 50% of market cap and absolute zero increase in asset/IP valuation. What was the purpose of that joke ? 🤪😊😎😜
0 · Reply
getsometoday
getsometoday Mar. 20 at 10:09 PM
$GLMD also one thing to consider after I read the bios of the people working there. There would be talent leaving if this didn’t stand a chance. They are all scientists. Probably a greatly overlooked canary in the coal mine.
1 · Reply
getsometoday
getsometoday Mar. 20 at 8:58 PM
$GLMD
0 · Reply
getsometoday
getsometoday Mar. 20 at 8:56 PM
$GLMD
0 · Reply
getsometoday
getsometoday Mar. 20 at 8:54 PM
$GLMD my inquiries were specifically around a phase 1b oncology human trial
0 · Reply
getsometoday
getsometoday Mar. 20 at 8:53 PM
$GLMD ok I rattled ChatGPT on this stock where we are now vs what we can expect or should hope to see in the coming weeks months.
0 · Reply
Lowlyme
Lowlyme Mar. 20 at 8:10 PM
$GLMD Jeff Bezos has all of my investing money. Thanks to my wife. Anyway at least he's enjoying his yatch. LM
0 · Reply
getsometoday
getsometoday Mar. 20 at 2:51 PM
$GLMD I think this is good news if they are recruiting they have the formulation and the meds ready to go to administer in this new method
1 · Reply
madan_shatri
madan_shatri Mar. 19 at 9:36 PM
$GLMD They have updated one of the studies on March 17. I don't know how much material info is this.
2 · Reply
BankOnTheFuture
BankOnTheFuture Mar. 19 at 3:46 PM
$GLMD Found out what was behind all the Form 3s issued. New SEC rule went into effect 3/16 for foreign issuers. The Form 3 filings don't mean anything other than the fact that Galmed is staying on top of SEC compliance.
1 · Reply
Latest News on GLMD
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Jan 30, 2026, 4:15 PM EST - 7 weeks ago

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Dec 8, 2025, 8:30 AM EST - 3 months ago

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Dec 4, 2025, 8:30 AM EST - 3 months ago

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Galmed Issues CEO Letter to Shareholders

Dec 1, 2025, 8:30 AM EST - 3 months ago

Galmed Issues CEO Letter to Shareholders

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 26, 2025, 8:30 AM EST - 4 months ago

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

Nov 18, 2025, 8:30 AM EST - 4 months ago

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

Nov 17, 2025, 8:30 AM EST - 4 months ago

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 28, 2025, 8:00 AM EDT - 7 months ago

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

Aug 25, 2025, 7:30 AM EDT - 7 months ago

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

May 27, 2025, 8:00 AM EDT - 10 months ago

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 22, 2025, 8:00 AM EDT - 10 months ago

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

May 6, 2025, 7:30 AM EDT - 11 months ago

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Apr 28, 2025, 8:00 AM EDT - 11 months ago

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Apr 17, 2025, 8:30 AM EDT - 1 year ago

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Apr 15, 2025, 8:30 AM EDT - 1 year ago

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Apr 2, 2025, 4:10 PM EDT - 1 year ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Mar 20, 2025, 8:55 AM EDT - 1 year ago

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Sep 25, 2024, 8:00 AM EDT - 1 year ago

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Apr 4, 2024, 5:06 PM EDT - 2 years ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Mar 15, 2024, 9:00 AM EDT - 2 years ago

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Nov 20, 2023, 4:32 PM EST - 2 years ago

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Sep 26, 2023, 8:30 AM EDT - 2 years ago

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jul 14, 2023, 9:30 AM EDT - 2 years ago

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Jul 10, 2023, 8:00 AM EDT - 2 years ago

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

Jun 1, 2023, 8:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

May 9, 2023, 7:00 AM EDT - 3 years ago

Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

Mar 29, 2023, 5:00 PM EDT - 3 years ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt

Feb 8, 2023, 8:00 AM EST - 3 years ago

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Dec 14, 2022, 5:00 PM EST - 3 years ago

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Aug 4, 2022, 8:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model

Jul 7, 2022, 8:27 AM EDT - 4 years ago

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

May 17, 2022, 8:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects

May 17, 2022, 7:30 AM EDT - 4 years ago

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

May 2, 2022, 7:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment

Apr 28, 2022, 7:00 AM EDT - 4 years ago

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2

Apr 26, 2022, 8:30 AM EDT - 4 years ago

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

Jan 11, 2022, 7:30 AM EST - 4 years ago

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study

Jan 10, 2022, 9:14 AM EST - 4 years ago

Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study

Galmed announces positive results of Phase 1 study of Amilo-5MER

Jan 10, 2022, 7:30 AM EST - 4 years ago

Galmed announces positive results of Phase 1 study of Amilo-5MER

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results

Nov 8, 2021, 7:30 AM EST - 4 years ago

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results

Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement

Nov 8, 2021, 7:00 AM EST - 4 years ago

Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement

Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study

Nov 1, 2021, 10:10 AM EDT - 4 years ago

Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study

Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine

Oct 11, 2021, 8:00 AM EDT - 4 years ago

Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine

Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action

Aug 19, 2021, 11:49 AM EDT - 4 years ago

Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action

Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound

Aug 19, 2021, 8:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound

MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study

Aug 16, 2021, 8:00 AM EDT - 4 years ago

MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

Aug 5, 2021, 7:00 AM EDT - 5 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late Stage NASH Trial

Aug 2, 2021, 9:26 AM EDT - 5 years ago

Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late Stage NASH Trial

madan_shatri
madan_shatri Mar. 21 at 10:15 AM
$GLMD What was the purpose of CEOs letter to SHs ? Short term valuation in terms of stock performance or asset/IP valuation ? Where is either of that ? From the day of that IMO SP lost 30% to 50% of market cap and absolute zero increase in asset/IP valuation. What was the purpose of that joke ? 🤪😊😎😜
0 · Reply
getsometoday
getsometoday Mar. 20 at 10:09 PM
$GLMD also one thing to consider after I read the bios of the people working there. There would be talent leaving if this didn’t stand a chance. They are all scientists. Probably a greatly overlooked canary in the coal mine.
1 · Reply
getsometoday
getsometoday Mar. 20 at 8:58 PM
$GLMD
0 · Reply
getsometoday
getsometoday Mar. 20 at 8:56 PM
$GLMD
0 · Reply
getsometoday
getsometoday Mar. 20 at 8:54 PM
$GLMD my inquiries were specifically around a phase 1b oncology human trial
0 · Reply
getsometoday
getsometoday Mar. 20 at 8:53 PM
$GLMD ok I rattled ChatGPT on this stock where we are now vs what we can expect or should hope to see in the coming weeks months.
0 · Reply
Lowlyme
Lowlyme Mar. 20 at 8:10 PM
$GLMD Jeff Bezos has all of my investing money. Thanks to my wife. Anyway at least he's enjoying his yatch. LM
0 · Reply
getsometoday
getsometoday Mar. 20 at 2:51 PM
$GLMD I think this is good news if they are recruiting they have the formulation and the meds ready to go to administer in this new method
1 · Reply
madan_shatri
madan_shatri Mar. 19 at 9:36 PM
$GLMD They have updated one of the studies on March 17. I don't know how much material info is this.
2 · Reply
BankOnTheFuture
BankOnTheFuture Mar. 19 at 3:46 PM
$GLMD Found out what was behind all the Form 3s issued. New SEC rule went into effect 3/16 for foreign issuers. The Form 3 filings don't mean anything other than the fact that Galmed is staying on top of SEC compliance.
1 · Reply
getsometoday
getsometoday Mar. 18 at 7:53 PM
$GLMD
1 · Reply
BankOnTheFuture
BankOnTheFuture Mar. 18 at 1:35 PM
$GLMD Peculiar. Nine different SEC form 3s filed today for various folks associated w/ Galmed. Form 3 is a statement of initial ownership. A large number of them are statements of options that were exercisable back in 2018-2020 for prices well in excess of today's price. Why file these forms now? Are they getting things cleaned up in preparation for something big like a buyout? Or am I just grasping at straws?
1 · Reply
getsometoday
getsometoday Mar. 18 at 12:26 AM
$GLMD
0 · Reply
madan_shatri
madan_shatri Mar. 17 at 12:28 AM
$GLMD How long this stock can hold range of $0.60 to $0.68 ?
3 · Reply
madan_shatri
madan_shatri Mar. 16 at 3:58 PM
$GLMD Ph1b study of Aramchol & Stivarga was expected to start in early 2026 and Ph3 NASH continues to be in suspension stage (I guess) since last 3 years ? They updated as 'suspended' in Feb again this yr. Lack of BP interests & funds means no progress on any trial. Reverse Split is already pre approved !! No Q4 2025 results and we are into end Q1 2026 ! Is there anyone doing some work or just enjoying on salaries & perks ?
1 · Reply
Lowlyme
Lowlyme Mar. 15 at 3:53 AM
$GLMD As someone who's gone through a few reverse splits and as many dilutions, oh and at least one of Allen's granting himself "incentive"shares, please let me know if anyone hears any other news. Like say trials. Best. Glta. LM
0 · Reply
madan_shatri
madan_shatri Mar. 14 at 12:39 AM
$GLMD Ph3 trial is suspended. They updated in Feb. Could there be separate spin out in works for Ph3 NASH trial ? Possibly yes. They gave this hint last year. IMO thats why they didn't dilute in Nov
2 · Reply
getsometoday
getsometoday Mar. 14 at 12:21 AM
$GLMD until 7/28 yall. So we have some time. Almost certain to get some pr before then
1 · Reply
Mile111
Mile111 Mar. 13 at 12:56 PM
$GLMD 100 Dollar ist comming 🤘😎
0 · Reply
getsometoday
getsometoday Mar. 12 at 9:16 PM
$GLMD dare I say holding up. Just marking time to the next pr may it be a doozy
0 · Reply
BankOnTheFuture
BankOnTheFuture Mar. 12 at 8:08 PM
$GLMD Looks like the guy who tries to walk it up at the close beat the guy who tries to walk it down at the close today.
0 · Reply
getsometoday
getsometoday Mar. 11 at 5:43 PM
$GLMD nice move for only 3700 shares traded. Would it kill Allen to buy 40,000 shares over the next few days and get us back over a buck
1 · Reply